8-K: Ekso Bionics Achieves Record Annual Revenue in 2023, Driven by Strong EksoHealth Demand

Ekso Bionics reported record annual revenue of $18.3 million for 2023, a 42% increase year-over-year, driven by strong demand for its EksoHealth devices.

Summary

• Ekso Bionics reported its financial results for the three and twelve months ended December 31, 2023.
• The company achieved record annual revenue of $18.3 million in 2023, a 42% increase compared to $12.9 million in 2022.
• A total of 151 EksoHealth units were sold in 2023.
• Fourth quarter revenue was $4.8 million, a 36% increase compared to $3.6 million in the same period in 2022, with 38 EksoHealth units sold.
• The company's gross profit for the full year was $9.1 million, representing a gross margin of approximately 50%.
• The net loss for the full year was $15.2 million, or $1.10 per share, compared to a net loss of $15.1 million, or $1.16 per share, in 2022.
• Cash on hand at the end of 2023 was $8.6 million, down from $20.5 million at the end of 2022.
• In January 2024, the company secured $3.9 million in net proceeds from a registered direct offering.
• Operating cash burn for the full year was $12.1 million, compared to $14.7 million in 2022.
• CMS has deferred payment determination for personal exoskeletons, including the Ekso Indego Personal, requesting additional data.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The record revenue and unit sales are strong positives, but the net loss and cash burn are concerning. The delay in CMS reimbursement is also a significant risk. Overall, the sentiment is cautiously optimistic.

Positives

• The company experienced a significant 42% increase in annual revenue, reaching a record $18.3 million.
• Ekso Bionics sold a record number of 151 EksoHealth units in 2023.
• Gross profit margins improved to approximately 50% for the full year, driven by lower device costs.
• The company's operating cash burn decreased to $12.1 million for the full year, compared to $14.7 million in 2022.
• The launch of GaitCoach software for EksoNR expands the company's product offerings.

Negatives

• The company reported a net loss of $15.2 million for the full year 2023.
• Cash on hand decreased significantly from $20.5 million at the end of 2022 to $8.6 million at the end of 2023.
• CMS has deferred payment determination for personal exoskeletons, which could impact future sales.
• Sales and marketing expenses increased to $8.5 million for the full year, primarily due to additional headcount from the HMC acquisition.
• Research and development expenses increased to $5.0 million for the full year, also due to the HMC acquisition.

Risks

• The company's ability to obtain adequate financing to fund and grow operations is a risk.
• The company faces the risk of not obtaining reimbursement from CMS at acceptable levels or at all.
• The development of the company's products is associated with significant time and resources.
• The company may fail to achieve broad market acceptance of its products.
• There is a risk of adverse results in future clinical studies of the company's medical device products.
• The company faces risks related to obtaining and maintaining patent protection and regulatory approvals.
• The company is subject to existing or increased competition and disruptions in the supply chain.
• The company may fail to successfully integrate the HMC business and its personnel.
• The company may fail to implement its business plans or strategies.

Future Outlook

The company believes its robust exoskeleton portfolio and commercial strategy position it well for long-term growth, but the company's future performance is subject to risks and uncertainties, including obtaining reimbursement from CMS and achieving market acceptance of its products.

Management Comments

• We are excited to have closed 2023 with record revenues driven by strong demand for our EksoHealth devices and expanded offerings across the continuum of care from hospital to home, said Scott Davis, Chief Executive Officer of Ekso Bionics.
• In support of our mission, we remain focused on expanding the reach of our exoskeleton devices to patients who can benefit the most.
• We believe the combination of our robust exoskeleton portfolio and the positive traction of our scalable commercial strategy position us well to drive long-term growth.

Industry Context

The announcement reflects the growing interest and adoption of exoskeleton technology in both medical and industrial applications. Ekso Bionics is positioning itself as a leader in this space, with a focus on expanding its reach and product offerings. The CMS decision on reimbursement is a key factor for the medical exoskeleton market.

Comparison to Industry Standards

• Ekso Bionics' 42% revenue growth is significant compared to the broader medical device industry, which typically sees single-digit growth rates.
• The company's gross margin of 50% is competitive within the medical device sector, but it is important to compare this to companies with similar product offerings.
• Companies like ReWalk Robotics and Cyberdyne also operate in the exoskeleton space, but their financial performance and market focus differ from Ekso Bionics.
• ReWalk Robotics, for example, has focused more on personal exoskeletons, while Ekso Bionics has a broader portfolio including industrial applications.
• Cyberdyne, based in Japan, has a strong presence in the Asian market, while Ekso Bionics is primarily focused on the US and European markets.
• The lack of a clear CMS reimbursement pathway for personal exoskeletons is a challenge for all companies in this sector.

Stakeholder Impact

• Shareholders may be encouraged by the record revenue and unit sales, but concerned about the net loss and cash burn.
• Employees may be impacted by the company's growth and expansion, as well as the integration of the HMC business.
• Customers may benefit from the company's expanded product offerings and the potential for CMS reimbursement.
• Suppliers may see increased demand for components and materials as the company grows.
• Creditors may be concerned about the company's cash burn and net loss.

Next Steps

• Ekso Bionics intends to provide pricing documentation to CMS as soon as possible.
• The company will continue to work with CMS to establish a reimbursement rate for personal exoskeletons.
• Management will host a conference call to discuss the financial results and recent business developments.

Key Dates

Keywords

exoskeleton, EksoHealth, medical devices, rehabilitation, wearable robots, revenue, gross profit, CMS, HMC, GaitCoach